Follow-up of the prevention-of-NEC study by Oncel et al. 2014 with evaluation of neurological, neurosensory and cognitive status at 18-24 months’ corrected age in premature infants given L. reuteri DSM 17938 during their stay as newborn at the neonatal intensive care unit. Four hundred (400) completed the trial, 370 were eligible for follow-up and 249 (62%) were evaluated, whereof 124 received L. reuteri and 125 the placebo.

There was no significant difference in any of the neurodevelopmental and sensory outcomes between the two groups. Height and weight at time were not reported.

Conclusion: Oral administration of L. reuteri DSM 17938 to very low birth weight infants to reduce the incidence and severity of NEC, started with the first feed, did not affect neuromotor, neurosensory, and cognitive outcomes at 18-24 months’ corrected age.

 

Reference

Akar M, Eras Z, Oncel MY, Arayici S, Guzoglu N, Canpolat FE, Uras N, Oguz SS. Impact of oral probiotics on neurodevelopmental outcomes in preterm infants. J Matern Fetal Neonatal Med. 5 May 2016,1-19. Epub ahead of print, doi:10.1080/14767058.2016.1174683. (Additional results of the Oncel 2014 trial.)

Crawling baby

For the avoidance of doubt, BioGaia’s products are food supplements, and the information on this part of the website should not be interpreted as our products are intended to diagnose, treat, cure or prevent any disease.

The information on this part of the website is intended only for health care and business professionals. If you are not a health care or business professional and would like to learn more about the indications BioGaia works with, please visit our Expertise pages.

Please read terms & conditions before accepting. By clicking on the button “I acknowledge and accept” you confirm that you are a healthcare or business professional and have read and understood this disclaimer including the terms and conditions.